DR. JOHN WILLIAM ERVIN M.D.
Prescription History 1629061213
Obstetrics & Gynecology in Tulsa, OK


Quality Rating: 77.69 out of 100 score

NPI Status: Active since August 30, 2005

Contact Information

4444 E 41ST ST
TULSA, OK
ZIP 74135
Phone: (918) 619-4400

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOHN WILLIAM ERVIN M.D., an active Obstetrics & Gynecology specialist practicing in Tulsa, OK. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 95 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 21 claims alone.

Medication Index

No matching medications currently found on file.

Combigan

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.5
Days Supply 527
OK State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills44.6
Peer Average Days Supply1,260
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.2% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,322.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$255.61

State Avg Cost Per Claim

$356.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 27.2
Days Supply 815
OK State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills80.9
Peer Average Days Supply2,413
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.7% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,420.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$118.41

State Avg Cost Per Claim

$46.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 21
30-Day Fills 31.7
Days Supply 908
OK State Average Benchmarks
Peer Average Claims100.0
Peer Average 30-Day Fills170.5
Peer Average Days Supply4,871
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.0% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $275.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.13

State Avg Cost Per Claim

$23.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 17
30-Day Fills 33.0
Days Supply 991
OK State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills67.0
Peer Average Days Supply1,920
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.5% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,560.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$680.05

State Avg Cost Per Claim

$445.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 308
OK State Average Benchmarks
Peer Average Claims90.0
Peer Average 30-Day Fills109.6
Peer Average Days Supply2,687
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.2% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $748.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.75

State Avg Cost Per Claim

$50.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Restasis

Generic Formulation: CyclosporineSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
OK State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills53.7
Peer Average Days Supply1,589
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.5% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,393.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$774.59

State Avg Cost Per Claim

$1,039.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOHN WILLIAM ERVIN M.D. provides transparency into local medical care patterns within Tulsa, OK.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.